INTRODUCTION
Imidazolium salts (IMSs) are best known for their applications in organic synthesis at room-temperature ionic liquids, or as precursors of stable carbenes, but they also show important biological properties such as antimicrobial activity. A large variety of these salts have been used as anti-inflammatory, antibacterial, antifungal and thromboxane synthetase enzyme inhibitor (Dominianni, Yen, 1989; Odzˇak, Skocˇıbušıc´, Maravıc´, 2013; Riduan, Zhang, 2013; Elshaarawy et al., 2014; Reinhardt et al., 2014) .
Imidazole derived NHC precursors are known in the field of organometallic chemistry for more than five decades and the imidazole ring presents a structural fragment that plays an important role in many biological systems such as enzymes, metallo-proteins as well as in natural products and anticancer drugs (Jaouen, 2006) . It also serves as a good ligand in various transition metal complexes (Navarro, Lippert, 2001) .
Several sites around IMS are amenable to modification: (i) the nitrogen substituents (1 and 12) and (ii) the backbone carbon substituents (2 and 13). IMSs were prepared with different alkyl and aryl groups to establish the contributions of the type and size of the substituents to the activity. The introduction of sterically hindered groups to the nitrogen atoms that are the part of aromatic rings were believed to influence the activity.
One of the first instances of the use of IMSs as an antimicrobial agent was reported by Demberelnymba et al. (2004) , in which a series of N-alkyl-N-methylimidazolium halides, and N-alkyl-N-hydroxyethylimidazolium chlorides were found to possess low MIC values against a range of microbes. They stated that the antibacterial and fungicidal activities were greatly affected by their chain length, the type of substituted functional groups, and their position in the imidazolium ring.
Based on these studies, we have discussed the synthesis and characterization of unsymmetrically substituted imidazolium salts and evaluated their antimicrobial properties.
MATERIAL AND METHODS

Material and measurements
1 H-and 13 C-NMR measurements were performed using a Varian Mercury 400 spectrometer operating at 400 and 100 MHz, respectively. NMR multiplicities are abbreviated as follows: s, singlet; d, doublet; t, triplet; m, multiplet signal. Coupling constants J are given in Hz. Melting points were measured in open capillary tubes with a Stuart-SMP30 melting point apparatus.
Synthesis of 1-5
A solution of N- (2,4,6-trimethylphenyl) imidazole (2.0 mmol) (Zeng et al., 2010) in toluene (10.0 mL) was added slowly to 2,4,6-trimethylbenzyl bromide/2,4,5,6-tetramethylbenzyl bromide/2,3,4,5,6-pentamethylbenzyl bromide (Van der Made, Van der Made, 1993) /1-bromoethanole/2-chloroethylamine hydrochloride (2.0 mmol) at 110 °C for 18 h. Diethylether (15.0 mL) was added to obtain a white crystalline solid which was filtered off. The solid was washed with Et 2 O (3×15.0 mL), and dried under vacuum. The crude product was recrystallized from CH 2 Cl 2 /Et 2 O (Compound for 1-3 Günay, Çoğaşlıoğlu, Fırıncı (2015) , compound 4,5 for Gençay (2013)).
Compound 1: N-(2,4,6-trimethylphenyl)-N'-(2,4,6-trimethylbenzyl) Compound 2: N- (2,4,6-trimethylphenyl)-N'-(2,3,5,6-tetramethylbenzyl) 4, 3, 4, 5, 4, 
Synthesis of 6
1-Ferrocenylethanol (1.0 mmol) and N-(2,4,6-trimethyphenyl)imidazole (1.1 mmol) were dissolved in acetic acid (3.0 mL) and stirred at 60 °C for 7 h. After removing most of acetic acid, a solution of LiCl (4.0 mmol) in EtOH (20.0 mL) was added, and stirred for 8 h at room temperature. After removing the volatiles, filtered through Celite, the crude was purified from CH 2 Cl 2 /Et 2 O (Yenisarı, 2014; Seo et al., 2003) . 
Synthesis of 7-9
These compounds were synthesized according to the method in the literature (Günay et al., 2009). Compound 7: N-(methyl)-N'-(2,3,5,6-tetramethylbenzyl) 8: N-(methyl)-N'-(2,3,4,5,6-pentamethylbenzyl) 
Synthesis of 10-12
These compounds were synthesized according to the literature method (Compounds for 10, 11 Günay et al. (2009) , compound for 12 Günay, Çoğaşlıoğlu (2016) 3, 5, 
Synthesis of 13, 14
These compounds were synthesized according to the literature method (Meyer, Taige, Strassner, 2009). Compound 13: N-(1-methyl-2-oxopropyl)-N'-(2,3,5,6-tetramethylbenzyl) (2,3,4,5,6-pentamethylbenzyl) Screenings for antimicrobial activities were carried out by the agar well diffusion method against test microorganisms (Collins et al., 2004; Clinical and Laboratory Standards Institute, 2015) . Fresh stock solutions (1000 µg mL -1 ) of the compounds were prepared in DMSO according to the needed concentrations for the experiments. The inoculum suspensions of the tested bacteria and yeasts were prepared from the broth cultures (18-24 h) and the turbidity equivalent adjusted to 0.5 McFarland standard tubes to give a concentration of 1 x 10 8 bacterial cells and 1 x 10 6 yeast cells/mL. To test the antimicrobial activity of each unsymmetrically substituted imidazolium salts, Mueller Hinton Agar medium (25 mL) was poured into each petri plate and was inoculated with 0.1 mL broth culture of bacteria or yeasts. Then using sterile cork borer of 6 mm diameter, wells were bored into the seeded agar plates and were loaded with a 50 µL volume of unsymmetrically substituted imidazolium salts.
Compound 14: N-(1-methyl-2-oxopropyl)-N'-
Plates o C for 24 h. After incubation, the diameter of the inhibition zone was measured. Discs of Chloramphenicol (C30, Oxoid), Gentamycin (GN10 Oxoid), Tetracycline (TE30), Erytromycine (E15), Ampicillin (AMP10) and Nystatine (NS100) were used as positive controls.
The minimum inhibitory concentrations (MIC) were determined for antimicrobial activities by preparing a microdilution broth (Jones et al., 1985; Jorgensen, Ferraro, 2009; CLSI, 2009) . All the bacteria were inoculated in the Nutrient Broth and incubated at 30-37 0 C for 24 h while the yeasts were inoculated in Malt Extract Broth and incubated at 30 0 C for 48 h. The compounds were dissolved in DMSO (2 mg mL -1 ). From the stock solution, two fold serial dilutions of the compounds were employed to determine the MIC ranging from 256 to 0.125 µg mL -1 . The lowest concentration of antimicrobial agent that resulted in complete inhibition of the microorganisms was represented as MIC (µg mL -1 ). As positive controls, Streptomycin (I.E. Ulagay) for bacteria and Nystatine (NS100, Oxoid) for yeast were used in the dilution method.
RESULTS AND DISCUSSION
Imidazole has been easily converted into IMSs by attachment of a wide variety of functional groups onto positions 1 and 3 of the imidazole ring. The target salts (1-14) shown in Figure 1 have been obtained by quaternization of 1-substituted imidazole by variously substituted benzyl halides. The IMSs were obtained as solids, which have been observed to be air stable, except compound 9, and soluble in chlorinated solvents and alcohol. The salts could be purified by recrystallization from ethanol or CH 2 Cl 2 (DCM) and by addition of Et 2 O. The IMSs were identified by NMR spectroscopy.
1 H-NMR chemical shifts were consistent with the proposed structures; the resonances for NCHN protons were observed as a sharp singlet between δ 9.47 and 10.39 ppm.
13 C-NMR of these salts showed the C2 carbon between δ 136.4 and 141.3 ppm. The representative 1 H-and 13 C-NMR spectra of the compounds 1, 2, 3, 6, 11 were given as Supplementary Data (Figure 1-10) .
FIGURE 1-Synthesis and formula of the imidazolium salts (1-14) used for antimicrobial activity.
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All of the compounds used in this study were tested for their in vitro antimicrobial activity by the agar well diffusion method. After then compounds showing antimicrobial activity were examined by MIC. Inhibition zones (mm) of the compounds were listed in Table I . In addition, the assay, were compared with knowing reference antibiotic and antifungal reagents. MIC values forming inhibition zone (mm) of the compounds were listed in Table II. Compounds 1 However, 1, 2 and 11 showed the lowest effects against B. thrungiensis, B. cereus ATCC 11778 and S. epidermidis ATCC 12228, respectively. For example, compound 1, 2 and 11 had effect 10 mm B. thrungiensis, 8 mm B. cereus ATCC 11778 and 9 mm S. epidermidis ATCC 12228, respectively On the other hand, 4, 5, 7, 8, 9, 10, 12, 13 and 14 had no effect on the test microorganisms examined (Table I) .
MIC values in Table II have also showed that some of the compounds tested presented noteworthy antimicrobial activity on the tested microorganisms. ), S. epidermidis ATCC 12228 (compound 11 = 256 μg mL -1 ). Micrococcus luteus does not regard as a pathogen bacteria but it can cause skin infections in individual with a decreased immune system such as new-born infants or patients with AIDS. The skin infections or chronic cutaneous infections result in pruritic eruptions of the skin in some areas as well as scattered papule lesions with or without central ulcerations (Smith et al., 1999) . Recently, this organism was recognized as an opportunistic pathogen and has been implicated in recurrent bacteraemia, septic shock, septic arthritis, endocarditis, meningitis, intracranial suppuration, and cavitating pneumonia in immunosuppressed patients (Greenblatt et al., 2004) .
Staphylococcus epidermidis generates biofilms to grow on plastic devices placed within the body (Costerton, Stewart, Greenberg, 2009 ). This happens most commonly on intravenous catheters and medical prostheses (Hedin, 1993) . Infection can also appear in dialysis patients or anyone with an implanted plastic device that may have been contaminated. It also causes endocarditis, most often in patients with defective heart valves. In some other cases, sepsis can occur in hospital patients. The spread of the infection has been shown reduced with the hand washing (Otto, 2009) . Compounds 4, 5, 7, 8, 9, 10, 12, 13 and 14 showed no antimicrobial activity. *Special gift from the Faculty of Medicine, Adnan Menderes University. 1: N- (2,4,6-trimethylphenyl)-N'-(2,4,6-trimethylbenzyl)imidazolium bromide, 2: N-(2,4,6-trimethylphenyl)-N'-(2,3,5,6-tetramethylbenzyl)imidazolium bromide, 3: N-(2,4,6-trimethylphenyl)-N'-(2,3,4,5,6-pentamethylbenzyl) imidazolium bromide, 4: N-(2,4,6-trimethylphenyl)-N'-(hydroxyethyl) imidazolium bromide, 5: N-(2,4,6-trimethylphenyl)-N'-(ethylamine) imidazolium chloride hydrochloride, 6: N-(ferrocenylethyl)-N'-(2,4,6-trimethylphenyl)imidazolium chloride, 7: N-(methyl)-N'-(2,3,5,6-tetramethylbenzyl)imidazolium bromide, 8: N-(methyl)-N'-(2,3,4,5,6-pentamethylbenzyl)imidazolium bromide, 9: N-(methyl)-N'-(2-methoxyethyl)imidazolium chloride, 10: N-(butyl)-N'-(2,4,6-trimethylbenzyl)imidazolium bromide, 11: N-(butyl)-N'-(2,3,5,6-tetramethylbenzyl) imidazolium bromide, 12: N-(butyl)-N'-(2,3,4,5,6-pentamethylbenzyl)imidazolium bromide, 13: N-(1-methyl-2-oxopropyl)-N'-(2,3,5,6-tetramethylbenzyl)imidazolium bromide, 14: N-(1-methyl-2-oxopropyl)-N'-(2,3,4,5,6-pentamethylbenzyl) imidazolium bromide. C30: Chloramphenicol (30 mg Oxoid); CN10: Gentamycin (10 mg, Oxoid); TE30: Tetracycline (30 mg, Oxoid); E15: Erytromycin (15 mg, Oxoid); AMP10: Ampicillin (10 mg, Oxoid); NS: Nystatine (100 mg, Oxoid).
